English

TFF Pharmaceuticals, Inc.

EDGAR

TFFP Quarterly report (10-Q) · filed 2024-11-20

30 filing records in this dataset, filed from 2019-08-20 to 2024-11-20. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

193 thousand USD

2024 Q3 · USD

Exact inputs and evidence

Revenue: 193387 USD Source

Operating margin

-1,852.26%

2024 Q3 · %

Exact inputs and evidence

Operating Income: -3582028 USD Source
Revenue: 193387 USD Source

Operating cash flow

-2 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -8400000 USD Source
Operating Cash Flow: -6400000 USD Source

Cash and cash equivalents: 2.6 million USD 2024-09-30 Source
Exact value

2600000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 3.54 million shares 2024-09-30 Source
Exact value

3538248 shares

Reported share-count change

-94.02% · -55.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

59133574 shares · 2023-09-30· Source
3538248 shares · 2024-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.16 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Revenue: 733871 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 619543 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 203273 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 650222 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 193387 USD · 2024-07-01 – 2024-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-11-20.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2023-12-31
Operating income: 6 of 11 periods available· newest 2023-12-31
Net income: 6 of 11 periods available· newest 2023-12-31
Operating cash flow: 6 of 11 periods available· newest 2023-12-31
Capital expenditure: 4 of 11 periods available· newest 2023-12-31
Total assets: 3 of 11 periods available· newest 2023-12-31
Total liabilities: 3 of 11 periods available· newest 2023-12-31
Current assets: 3 of 11 periods available· newest 2023-12-31
Current liabilities: 3 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+48%

Prior period

USD 495,805

2022-01-01 – 2022-12-31
Current period

USD 733,871

2023-01-01 – 2023-12-31

Exact inputs and evidence

733871 − 495805 = 238066 USD

495805 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
733871 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Year-over-year change in Revenue: 238066 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 733871 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#621222 Filing: 000121390024027185 Input fundies:Revenue: 495805 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#621934 Filing: 000121390024027185
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 10.6 million

Prior period

−USD 31.8 million

2022-01-01 – 2022-12-31
Current period

−USD 21.2 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-21200000 − -31800000 = 10600000 USD

-31800000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-21200000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Year-over-year change in Net income: 10600000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -21200000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793254 Filing: 000121390024027185 Input fundies:NetIncome: -31800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793441 Filing: 000121390024027185
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 11.3 million

Prior period

−USD 27.3 million

2022-01-01 – 2022-12-31
Current period

−USD 16 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-16000000 − -27300000 = 11300000 USD

-27300000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-16000000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Year-over-year change in Operating cash flow: 11300000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -16000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793676 Filing: 000121390024027185 Input fundies:OperatingCashFlow: -27300000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793892 Filing: 000121390024027185
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-93.9%

Prior period

USD 1.55 million

2022-01-01 – 2022-12-31
Current period

USD 94,750

2023-01-01 – 2023-12-31

Exact inputs and evidence

94750 − 1551326 = -1456576 USD

1551326 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
94750 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Year-over-year change in Capital expenditure: -1456576 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 94750 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#745564 Filing: 000121390024027185 Input fundies:CapitalExpenditure: 1551326 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#746266 Filing: 000121390024027185
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 733,871 100% of revenue
Operating costs Derived USD 22.63 million 3,083% of revenue
Operating income −USD 21.89 million −2,983% of revenue
Tax, interest and other Derived −USD 694,662 −95% of revenue
Net income −USD 21.2 million −2,889% of revenue

Cash

Operating cash flow −USD 16 million −2,180% of revenue
Capital expenditure USD 94,750 13% of revenue
Free cash flow Derived −USD 16.09 million −2,193% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 36,155% of revenue.
2022 Operating loss: operating costs were 6,513% of revenue.
2023 Operating loss: operating costs were 3,083% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	88161	31874819 Derived	-31786658	-747946 Derived	-31038712	-30425476 Derived	Source 2021-01-01 – 2021-12-31: 88161 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -31786658 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -31038712 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -29556971 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 868505 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	495805	32292595 Derived	-31796790	3210 Derived	-31800000	-28851326 Derived	Source 2022-01-01 – 2022-12-31: 495805 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -31796790 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -31800000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -27300000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1551326 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	733871	22628533 Derived	-21894662	-694662 Derived	-21200000	-16094750 Derived	Source 2023-01-01 – 2023-12-31: 733871 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -21894662 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -21200000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -16000000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 94750 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 733.9K 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	88161	Revenue: 88161 Open source
20222022-12-31	Revenue	495805	Revenue: 495805 Open source
20232023-12-31	Revenue	733871	Revenue: 733871 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

48% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 88161 Open source
20222022-12-31	Year over year	462.4%	Revenue: 495805 Open source Revenue: 88161 Open source
20232023-12-31	Year over year	48%	Revenue: 733871 Open source Revenue: 495805 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -2,983.4% 2023

Net margin -2,888.8% 2023

Free cash flow margin -2,193.1% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-36,055.2%	Operating Income: -31786658 Open source Revenue: 88161 Open source
20222022-12-31	Operating margin	-6,413.2%	Operating Income: -31796790 Open source Revenue: 495805 Open source
20232023-12-31	Operating margin	-2,983.4%	Operating Income: -21894662 Open source Revenue: 733871 Open source
20212021-12-31	Net margin	-35,206.9%	Net Income: -31038712 Open source Revenue: 88161 Open source
20222022-12-31	Net margin	-6,413.8%	Net Income: -31800000 Open source Revenue: 495805 Open source
20232023-12-31	Net margin	-2,888.8%	Net Income: -21200000 Open source Revenue: 733871 Open source
20212021-12-31	Free cash flow margin	-34,511.3%	Revenue: 88161 Open source Operating Cash Flow: -29556971 Open source Capital Expenditure: 868505 Open source
20222022-12-31	Free cash flow margin	-5,819.1%	Revenue: 495805 Open source Operating Cash Flow: -27300000 Open source Capital Expenditure: 1551326 Open source
20232023-12-31	Free cash flow margin	-2,193.1%	Revenue: 733871 Open source Operating Cash Flow: -16000000 Open source Capital Expenditure: 94750 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -16M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-29556971	Operating Cash Flow: -29556971 Open source
20222022-12-31	Operating cash flow	-27300000	Operating Cash Flow: -27300000 Open source
20232023-12-31	Operating cash flow	-16000000	Operating Cash Flow: -16000000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -16.1M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-30425476	Operating Cash Flow: -29556971 Open source Capital Expenditure: 868505 Open source
20222022-12-31	Free cash flow	-28851326	Operating Cash Flow: -27300000 Open source Capital Expenditure: 1551326 Open source
20232023-12-31	Free cash flow	-16094750	Operating Cash Flow: -16000000 Open source Capital Expenditure: 94750 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

20.5% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	4.8%	Total Liabilities: 1960752 Open source Total Assets: 40697811 Open source
20222022-12-31	Liabilities / assets	5.1%	Total Liabilities: 1240756 Open source Total Assets: 24120215 Open source
20232023-12-31	Liabilities / assets	20.5%	Total Liabilities: 2460282 Open source Total Assets: 12027316 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.13× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	19.81×	Current Assets: 38837951 Open source Current Liabilities: 1960752 Open source
20222022-12-31	Current assets / current liabilities	16.83×	Current Assets: 19025166 Open source Current Liabilities: 1130662 Open source
20232023-12-31	Current assets / current liabilities	3.13×	Current Assets: 7590318 Open source Current Liabilities: 2428540 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-24 – 2018-12-31	−USD 3.84 million Exact value Exact value: -3842186 USD 2018-01-24 – 2018-12-31: -3842186 USD Inspect Net Income Open source Share or cite Citation for Net Income · TFF Pharmaceuticals, Inc. · 2018-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Net Income: -3842186 USD Concept: fundies:NetIncome Period: 2018-01-24 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-24&unit=USD&dimensions= Input fundies:NetIncome: -3842186 USD (2018-01-24 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390020007544/tffp-20191231.xml#92330 Filing: 000121390020007544 The citation records this snapshot. The page link may show a newer release later.	−USD 2.13 million Exact value Exact value: -2126988 USD 2018-01-24 – 2018-12-31: -2126988 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TFF Pharmaceuticals, Inc. · 2018-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Operating Cash Flow: -2126988 USD Concept: fundies:OperatingCashFlow Period: 2018-01-24 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-24&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2126988 USD (2018-01-24 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390020007544/tffp-20191231.xml#96674 Filing: 000121390020007544 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 11.87 million Exact value Exact value: -11870228 USD 2019-01-01 – 2019-12-31: -11870228 USD Inspect Net Income Open source Share or cite Citation for Net Income · TFF Pharmaceuticals, Inc. · 2019-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Net Income: -11870228 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11870228 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390021014575/tffp-20201231.xml#58042 Filing: 000121390021014575 The citation records this snapshot. The page link may show a newer release later.	−USD 11.22 million Exact value Exact value: -11216122 USD 2019-01-01 – 2019-12-31: -11216122 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TFF Pharmaceuticals, Inc. · 2019-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Operating Cash Flow: -11216122 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11216122 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390021014575/tffp-20201231.xml#74361 Filing: 000121390021014575 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 18.57 million Exact value Exact value: -18567234 USD 2020-01-01 – 2020-12-31: -18567234 USD Inspect Net Income Open source Share or cite Citation for Net Income · TFF Pharmaceuticals, Inc. · 2020-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Net Income: -18567234 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18567234 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390022014844/f10k2021_tffpharma.htm#862477 Filing: 000121390022014844 The citation records this snapshot. The page link may show a newer release later.	−USD 16.62 million Exact value Exact value: -16615589 USD 2020-01-01 – 2020-12-31: -16615589 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TFF Pharmaceuticals, Inc. · 2020-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Operating Cash Flow: -16615589 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16615589 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390022014844/f10k2021_tffpharma.htm#927384 Filing: 000121390022014844 The citation records this snapshot. The page link may show a newer release later.	USD 1.1 million Exact value Exact value: 1102808 USD 2020-01-01 – 2020-12-31: 1102808 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TFF Pharmaceuticals, Inc. · 2020-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Capital Expenditure: 1102808 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1102808 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390022014844/f10k2021_tffpharma.htm#931953 Filing: 000121390022014844 The citation records this snapshot. The page link may show a newer release later.	−USD 17.72 million Calculation and evidence -16615589 − 1102808 USD Exact free cash flow: -17718397 USD 2020-01-01 – 2020-12-31: -16615589 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1102808 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TFF Pharmaceuticals, Inc. · 2020-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Free cash flow: -17718397 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16615589 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390022014844/f10k2021_tffpharma.htm#927384 Filing: 000121390022014844 Input fundies:CapitalExpenditure: 1102808 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390022014844/f10k2021_tffpharma.htm#931953 Filing: 000121390022014844 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 31.04 million Exact value Exact value: -31038712 USD 2021-01-01 – 2021-12-31: -31038712 USD Inspect Net Income Open source Share or cite Citation for Net Income · TFF Pharmaceuticals, Inc. · 2021-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Net Income: -31038712 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31038712 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390023025454/f10k2022_tffpharma.htm#821047 Filing: 000121390023025454 The citation records this snapshot. The page link may show a newer release later.	−USD 29.56 million Exact value Exact value: -29556971 USD 2021-01-01 – 2021-12-31: -29556971 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TFF Pharmaceuticals, Inc. · 2021-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Operating Cash Flow: -29556971 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29556971 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390023025454/f10k2022_tffpharma.htm#892276 Filing: 000121390023025454 The citation records this snapshot. The page link may show a newer release later.	USD 868,505 Exact value Exact value: 868505 USD 2021-01-01 – 2021-12-31: 868505 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TFF Pharmaceuticals, Inc. · 2021-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Capital Expenditure: 868505 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 868505 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390023025454/f10k2022_tffpharma.htm#897696 Filing: 000121390023025454 The citation records this snapshot. The page link may show a newer release later.	−USD 30.43 million Calculation and evidence -29556971 − 868505 USD Exact free cash flow: -30425476 USD 2021-01-01 – 2021-12-31: -29556971 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 868505 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TFF Pharmaceuticals, Inc. · 2021-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Free cash flow: -30425476 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29556971 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390023025454/f10k2022_tffpharma.htm#892276 Filing: 000121390023025454 Input fundies:CapitalExpenditure: 868505 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390023025454/f10k2022_tffpharma.htm#897696 Filing: 000121390023025454 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 31.8 million Exact value Exact value: -31800000 USD 2022-01-01 – 2022-12-31: -31800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TFF Pharmaceuticals, Inc. · 2022-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Net Income: -31800000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793441 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.	−USD 27.3 million Exact value Exact value: -27300000 USD 2022-01-01 – 2022-12-31: -27300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TFF Pharmaceuticals, Inc. · 2022-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Operating Cash Flow: -27300000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27300000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793892 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.	USD 1.55 million Exact value Exact value: 1551326 USD 2022-01-01 – 2022-12-31: 1551326 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TFF Pharmaceuticals, Inc. · 2022-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Capital Expenditure: 1551326 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1551326 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#746266 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.	−USD 28.85 million Calculation and evidence -27300000 − 1551326 USD Exact free cash flow: -28851326 USD 2022-01-01 – 2022-12-31: -27300000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1551326 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TFF Pharmaceuticals, Inc. · 2022-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Free cash flow: -28851326 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27300000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793892 Filing: 000121390024027185 Input fundies:CapitalExpenditure: 1551326 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#746266 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 21.2 million Exact value Exact value: -21200000 USD 2023-01-01 – 2023-12-31: -21200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Net Income: -21200000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21200000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793254 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.	−USD 16 million Exact value Exact value: -16000000 USD 2023-01-01 – 2023-12-31: -16000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Operating Cash Flow: -16000000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793676 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.	USD 94,750 Exact value Exact value: 94750 USD 2023-01-01 – 2023-12-31: 94750 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Capital Expenditure: 94750 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 94750 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#745564 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.	−USD 16.09 million Calculation and evidence -16000000 − 94750 USD Exact free cash flow: -16094750 USD 2023-01-01 – 2023-12-31: -16000000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 94750 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TFF Pharmaceuticals, Inc. · 2023-12-31 TFF Pharmaceuticals, Inc. (edgar:1733413) Free cash flow: -16094750 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1733413?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#793676 Filing: 000121390024027185 Input fundies:CapitalExpenditure: 94750 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm#745564 Filing: 000121390024027185 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

30 filings · 1,216 latest values · 1,216 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001733413, 1733413, TFFP, edgar:1733413

Also known as TFF Pharmaceuticals, Inc., TFF PHARMACEUTICALS, INC., TFF PHARMACEUTICALS, Inc., TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation